Fusafungine

Fusafungine (INN), also known as fusafungin, is an active agent used in antibiotics for treatment of nasal and throat infection. It also possesses anti-inflammatory properties. Fusafungine is a mixture of enniatin cyclohexadepsipeptides made up of alternating D-α-hydroxyvaleric acid and L-N-methylamino acid residues,^[1] produced by the ascomycete Fusarium lateritium, and marketed by Servier under the trade names Locabiotal, Bioparox, and Locabiosol.

Fusafungine

Clinical data
Other names	Fusafungin
AHFS/Drugs.com	International Drug Names
ATC code	R02AB03 (WHO)
Identifiers
IUPAC name cyclo[N-oxa-DL-valyl-N-methyl-L-valyl-N-oxa-DL-valyl-N-methyl-L-valyl-N-oxa-DL-valyl-N-methyl-L-valyl]
CAS Number	1393-87-9 Y
PubChem CID	3084092
DrugBank	DB08965 N
UNII	65DD690W0C
KEGG	D08002 N
CompTox Dashboard (EPA)	DTXSID50912008
ECHA InfoCard	100.014.306
Chemical and physical data
Formula	C33H57N3O9
Molar mass	639.831 g·mol−1
3D model (JSmol)	Interactive image
Melting point	125 to 129 °C (257 to 264 °F)
SMILES CC(C)[C@H]1C(=O)OC(C(=O)N([C@H](C(=O)OC(C(=O)N([C@H](C(=O)OC(C(=O)N1C)C(C)C)C(C)C)C)C(C)C)C(C)C)C)C(C)C
NY (what is this?)  (verify)

According to a pooled analysis study done in the UK for the efficacy of fusafungine in rhinopharingitis, it was found that the proportion of patients who showed an improvement in symptoms from Day 0 to Day 4 of infection was 61.5% with fusafungine vs. 46.8% when compared to a placebo.^[2]

In February 2016, the European Medicines Agency recommended the withdrawal of fusafungine from the market due to rare but severe allergic reactions (mainly bronchospasms).^[3]